BlackRock’s Atara Biotherapeutics ATRA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $970K | Buy |
84,455
+5,433
| +7% | +$43.3K | ﹤0.01% | 4363 |
|
|
2026
Q1 | $374K | Buy |
79,022
+11,914
| +18% | +$72.7K | ﹤0.01% | 4600 |
|
|
2025
Q4 | $1.21M | Sell |
67,108
-2,725
| -4% | -$40.7K | ﹤0.01% | 4248 |
|
|
2025
Q3 | $1M | Sell |
69,833
-1,015
| -1% | -$11.7K | ﹤0.01% | 4283 |
|
|
2025
Q2 | $547K | Buy |
70,848
+10,050
| +17% | +$73.3K | ﹤0.01% | 4419 |
|
|
2025
Q1 | $361K | Sell |
60,798
-48
| -0.1% | -$419 | ﹤0.01% | 4472 |
|
|
2024
Q4 | $810K | Sell |
60,846
-108
| -0.2% | -$1.14K | ﹤0.01% | 4273 |
|
|
2024
Q3 | $496K | Sell |
60,954
-191
| -0.3% | -$1.64K | ﹤0.01% | 4332 |
|
|
2024
Q2 | $520K | Sell |
61,145
-212,114
| -78% | -$3.19M | ﹤0.01% | 4334 |
|
|
2024
Q1 | $4.74M | Sell |
273,259
-10,230
| -4% | -$182K | ﹤0.01% | 3688 |
|
|
2023
Q4 | $3.63M | Sell |
283,489
-24,348
| -8% | -$568K | ﹤0.01% | 3820 |
|
|
2023
Q3 | $11.4M | Sell |
307,837
-22,693
| -7% | -$1.01M | ﹤0.01% | 3256 |
|
|
2023
Q2 | $13.3M | Sell |
330,530
-40,322
| -11% | -$2.28M | ﹤0.01% | 3281 |
|
|
2023
Q1 | $26.9M | Buy |
370,852
+4,766
| +1% | +$462K | ﹤0.01% | 2821 |
|
|
2022
Q4 | $30M | Buy |
366,086
+9,606
| +3% | +$1M | ﹤0.01% | 2804 |
|
|
2022
Q3 | $33.7M | Buy |
356,480
+5,892
| +2% | +$662K | ﹤0.01% | 2729 |
|
|
2022
Q2 | $68.3M | Buy |
350,588
+38,582
| +12% | +$6.3M | ﹤0.01% | 2277 |
|
|
2022
Q1 | $72.5M | Sell |
312,006
-656
| -0.2% | -$209K | ﹤0.01% | 2346 |
|
|
2021
Q4 | $123M | Buy |
312,662
+6,598
| +2% | +$2.78M | ﹤0.01% | 2065 |
|
|
2021
Q3 | $137M | Sell |
306,064
-2,737
| -0.9% | -$981K | ﹤0.01% | 2000 |
|
|
2021
Q2 | $120M | Buy |
308,801
+30,837
| +11% | +$11M | ﹤0.01% | 2140 |
|
|
2021
Q1 | $99.8M | Buy |
277,964
+19,787
| +8% | +$8.75M | ﹤0.01% | 2194 |
|
|
2020
Q4 | $127M | Buy |
258,177
+22,498
| +10% | +$10.4M | ﹤0.01% | 1927 |
|
|
2020
Q3 | $76.4M | Buy |
235,679
+30,429
| +15% | +$10.4M | ﹤0.01% | 2054 |
|
|
2020
Q2 | $74.8M | Buy |
205,250
+22,639
| +12% | +$5.72M | ﹤0.01% | 2024 |
|
|
2020
Q1 | $38.9M | Sell |
182,611
-606
| -0.3% | -$192K | ﹤0.01% | 2212 |
|
|
2019
Q4 | $75.4M | Buy |
183,217
+5,271
| +3% | +$1.82M | ﹤0.01% | 2119 |
|
|
2019
Q3 | $62.8M | Buy |
177,946
+24,288
| +16% | +$9.06M | ﹤0.01% | 2154 |
|
|
2019
Q2 | $77.3M | Buy |
153,658
+14,281
| +10% | +$10.1M | ﹤0.01% | 2070 |
|
|
2019
Q1 | $139M | Sell |
139,377
-1,152
| -0.8% | -$1.07M | 0.01% | 1673 |
|
|
2018
Q4 | $122M | Buy |
140,529
+898
| +0.6% | +$834K | 0.01% | 1661 |
|
|
2018
Q3 | $144M | Buy |
139,631
+5,047
| +4% | +$4.93M | 0.01% | 1712 |
|
|
2018
Q2 | $124M | Buy |
134,584
+20,806
| +18% | +$22.4M | 0.01% | 1807 |
|
|
2018
Q1 | $111M | Buy |
113,778
+35,288
| +45% | +$32.2M | 0.01% | 1774 |
|
|
2017
Q4 | $35.5M | Sell |
78,490
-1,216
| -2% | -$449K | ﹤0.01% | 2474 |
|
|
2017
Q3 | $33M | Buy |
79,706
+2,765
| +4% | +$1.04M | ﹤0.01% | 2529 |
|
|
2017
Q2 | $26.9M | Buy |
76,941
+7,893
| +11% | +$3.04M | ﹤0.01% | 2624 |
|
|
2017
Q1 | $35.5M | Buy |
69,048
+68,549
| +13,737% | +$28.4M | ﹤0.01% | 2427 |
|
|
2016
Q4 | $177K | Sell |
499
-9
| -2% | -$3.81K | ﹤0.01% | 2222 |
|
|
2016
Q3 | $272K | Buy |
508
+264
| +108% | +$143K | ﹤0.01% | 1998 |
|
|
2016
Q2 | $137K | Buy |
244
+201
| +467% | +$96.5K | ﹤0.01% | 2335 |
|
|
2016
Q1 | $20K | Buy |
43
+23
| +115% | +$10.4K | ﹤0.01% | 2839 |
|
|
2015
Q4 | $13K | Sell |
20
-21
| -51% | -$15.9K | ﹤0.01% | 2754 |
|
|
2015
Q3 | $32K | Buy |
41
+28
| +215% | +$34.1K | ﹤0.01% | 2117 |
|
|
2015
Q2 | $17K | Buy |
13
+7
| +117% | +$8.03K | ﹤0.01% | 2468 |
|
|
2015
Q1 | $6K | Hold |
6
| – | – | ﹤0.01% | 2966 |
|
|
2014
Q4 | $4K | Buy |
+6
| New | +$3.66K | ﹤0.01% | 3103 |
|
Other funds holding ATRA
VCM
SCA
VFT
BlackRock's ATRA Position: Q2 2026 in Review
BlackRock increased its Atara Biotherapeutics (ATRA) stake by 6.9% in Q2 2026, buying an estimated $43.3K and bringing the position to 84,455 shares worth $970K. The position accounts for ﹤0.01% of the portfolio, ranked #4363.
BlackRock first reported a position in ATRA in Q4 2014 and has held it in 47 quarters since. The position peaked at $144M in Q3 2018. 21 funds tracked by Wall St. Rank hold ATRA as of Q2 2026.
- BlackRock held 84,455 shares of Atara Biotherapeutics worth $970K as of Q2 2026.
- BlackRock bought 5,433 Atara Biotherapeutics shares in Q2 2026, an estimated $43.3K.
- Atara Biotherapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4363 holding.
- BlackRock first reported a position in Atara Biotherapeutics in Q4 2014 and has held it in 47 quarters since.
- BlackRock's Atara Biotherapeutics position peaked at $144M in Q3 2018.
- 21 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2026.
Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.